Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lurasidone - Sumitomo Pharma

Next Previous
X
Search
Drug Profile

Lurasidone - Sumitomo Pharma

Alternative Names: DSP-1349M; Latuda; Lurasidone HCl; Lurasidone hydrochloride; Lurasidone injectable suspension; Lurasidone injection suspension; SM-13496; SMP-13496

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Angelini Group; Bukwang Pharmaceutical; Daiichi Sankyo Company; DKSH Singapore; DKSH Thailand; Standard Chemical & Pharmaceutical Company; Sumitomo Pharma; Sumitomo Pharma America; Takeda
  • Class Antidepressants; Antipsychotics; Cyclohexanes; Isoindoles; Piperazines; Small molecules; Thiazoles
  • Mechanism of Action 5-HT1A serotonin receptor agonists; Dopamine D2 receptor antagonists; Serotonin 2C receptor antagonists; Serotonin 5-HT2A receptor antagonists; Serotonin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bipolar depression; Schizophrenia
  • Preregistration Bipolar disorders
  • Phase III Autistic disorder; Major depressive disorder; Psychiatric disorders

Most Recent Events

  • 21 Feb 2023 First generic equivalent launched in USA by Lupin
  • 31 Jan 2023 Discontinued - Phase-III for Bipolar depression in China (PO) prior to January 2023
  • 12 Jan 2023 Sumitomo Pharmaceutical and Sunivion terminates a phase III trial in Bipolar depression in China (PO) due to company's business decision (NCT04383691)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top